CLOs on the Move

Fruit Street

www.fruitstreet.com

 
Fruit Street delivers the CDC`s Diabetes Prevention Program using telehealth, wearable devices, and mobile applications. The diabetes prevention program is a 1-year long diet and lifestyle intervention designed to help pre-diabetic patients lose 5-7% of their weight through diet and lifestyle changes. The program is based on clinical research that was published in the New England Journal of Medicine in 2002 which showed that patients who complete the program have a 58% risk reduction for developing diabetes.
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Biography Identity

Biography Identity is a Bellingham, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hall Ira

Hall Ira is a Sauquoit, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ninos Latinos Unidos

Ninos Latinos Unidos is a Colton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MIDWEST OPTICAL SYSTEMS

MIDWEST OPTICAL SYSTEMS, INC. is a Palatine, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.